HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Staels, B. Articles by Auwerx, J. Search for Related Content PubMed PubMed Citation Articles by Staels, B. Articles by Auwerx, J. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 33, 727-735, Copyright © 1992 by Lipid Research, Inc.

ARTICLES

Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates

B Staels, A van Tol, G Skretting and J Auwerx
Department of Developmental Biology, Gasthuisberg, Katholieke Universiteit Leuven, Belgium.

Plasma lipoprotein metabolism is influenced by several factors that may act by regulating the expression of proteins involved in lipoprotein metabolism, such as lecithin:cholesterol acyltransferase (LCAT). We determined the influence of several hormones and hypolipidemic drugs on hepatic LCAT gene expression and plasma LCAT activity. Liver LCAT mRNA levels were resistant to regulation by the hormones ethinylestradiol, L- thyroxine, hydrocortisone, or by the hypolipidemic drugs probucol, simvastatin, and nicotinic acid. In contrast, hepatic LCAT mRNA levels decreased to 67%, 64%, and 46% of the control levels after treatment with the fibric acid derivatives clofibrate, gemfibrozil, and fenofibrate, respectively. Fenofibrate lowered liver LCAT mRNA levels in a dose-dependent manner, which was paralleled by a decrease in plasma LCAT activity to 54% of the controls at a dose of 0.5% (w/w) in rat chow. The decrease in liver LCAT mRNA levels was maximal after 1 day, whereas the fall in plasma LCAT activity trailed by 2 days. Cessation of treatment with fenofibrate restored liver LCAT mRNA levels to control levels within 1 week. The transcription rate of the LCAT gene decreased by 25% in nuclei isolated from fenofibrate-treated rat liver, thereby indicating that hepatic LCAT gene expression is, at least partly, regulated at a transcriptional level. In contrast to the liver, brain and testis LCAT mRNA levels remained constant after treatment with fenofibrate, indicating that fibrates regulate LCAT gene expression in a tissue-selective manner.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. S. Millar, D. Duffy, R. Gadi, L. T. Bloedon, R. L. Dunbar, M. L. Wolfe, R. Movva, A. Shah, I. V. Fuki, M. McCoy, et al. Potent and Selective PPAR-{alpha} Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 140 - 146. [Abstract] [Full Text] [PDF]

				R. P. F. Dullaart, F. Perton, W. J. Sluiter, R. de Vries, and A. van Tol Plasma Lecithin: Cholesterol Acyltransferase Activity Is Elevated in Metabolic Syndrome and Is an Independent Marker of Increased Carotid Artery Intima Media Thickness J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4860 - 4866. [Abstract] [Full Text] [PDF]

				T. Fu, K. F. Kozarsky, and J. Borensztajn Overexpression of SR-BI by Adenoviral Vector Reverses the Fibrateinduced Hypercholesterolemia of Apolipoprotein E-deficient Mice J. Biol. Chem., December 26, 2003; 278(52): 52559 - 52563. [Abstract] [Full Text] [PDF]

				O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 717 - 726. [Abstract] [Full Text] [PDF]

				A. Soria, C. Bocos, and E. Herrera Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats J. Lipid Res., January 1, 2002; 43(1): 74 - 81. [Abstract] [Full Text] [PDF]

				P. Gervois, I. P. Torra, G. Chinetti, T. Grötzinger, G. Dubois, J.-C. Fruchart, J. Fruchart-Najib, E. Leitersdorf, and B. Staels A Truncated Human Peroxisome Proliferator-Activated Receptor {alpha} Splice Variant with Dominant Negative Activity Mol. Endocrinol., September 1, 1999; 13(9): 1535 - 1549. [Abstract] [Full Text]

				P. Gervois, S. Chopin-Delannoy, A. Fadel, G. Dubois, V. Kosykh, J.-C. Fruchart, J. Najïb, V. Laudet, and B. Staels Fibrates Increase Human REV-ERB{alpha} Expression in Liver via a Novel Peroxisome Proliferator-Activated Receptor Response Element Mol. Endocrinol., March 1, 1999; 13(3): 400 - 409. [Abstract] [Full Text]

				N. Vu-Dac, S. Chopin-Delannoy, P. Gervois, E. Bonnelye, G. Martin, J.-C. Fruchart, V. Laudet, and B. Staels The Nuclear Receptors Peroxisome Proliferator-activated Receptor alpha  and Rev-erbalpha Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates J. Biol. Chem., October 2, 1998; 273(40): 25713 - 25720. [Abstract] [Full Text] [PDF]

				T. V. Fungwe, B. J. Kudchodkar, A. G. Lacko, and L. Dory Fatty Acids Modulate Lecithin:Cholesterol Acyltransferase Secretion Independently of Effects on Triglyceride Secretion in Primary Rat Hepatocytes J. Nutr., August 1, 1998; 128(8): 1270 - 1275. [Abstract] [Full Text]

				K. L. Hoppe and O. L. Francone Binding and functional effects of transcription factors Sp1 and Sp3 on the proximal human lecithin:cholesterol acyltransferase promoter J. Lipid Res., May 1, 1998; 39(5): 969 - 977. [Abstract] [Full Text]

				M. Bouly, D. Masson, B. Gross, X.-c. Jiang, C. Fievet, G. Castro, A. R. Tall, J.-C. Fruchart, B. Staels, L. Lagrost, et al. Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate J. Biol. Chem., July 6, 2001; 276(28): 25841 - 25847. [Abstract] [Full Text] [PDF]